Core Viewpoint - The company, InnoCare Pharma-B (09606), announced that its DB-1303/BNT323 has met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes, as evaluated by an independent data monitoring committee (IDMC) [1] Group 1 - The Phase III clinical trial is a randomized, controlled, open-label, multi-center study conducted in China [1] - The trial aims to assess the efficacy and safety of DB-1303 compared to T-DM1 in the specified patient population [1] - Following the interim analysis results, the company plans to communicate with the National Medical Products Administration (NMPA) in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]